ARENA PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $54,000 | $319,000 | $806.4M | $18.0M | $21.3M | $92.2M |
| Operating income | −$624.3M | −$426.6M | $482.7M | −$144.8M | −$92.0M | −$5.3M |
| Net income | −$616.4M | −$404.7M | $397.6M | −$29.4M | −$91.4M | −$22.5M |
| Total assets | $784.7M | $1.19B | $1.17B | $686.9M | $339.3M | $169.0M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $673.2M | $1.08B | $1.07B | $606.3M | $207.1M | $39.9M |
| EPS (diluted) | $-10.14 | $-2.00 | $12.10 | $-0.63 | $-2.77 | $-0.89 |
| Shares out. | 60.3M | 50.2M | 49.5M | 39.4M | 245.5M | 242.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −1156109.3%
- Net margin
- −1141542.6%
- Return on equity
- −91.6%
- Return on assets
- −78.6%
- Return on capital (ROCE)
- −86.9%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $11.16
- Revenue growth (YoY)
- −83.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Accruals / assets
- −21.0%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 11, 2022
- Other material eventMar 10, 2022
- Results of operationsFeb 23, 2022
- Other material eventFeb 7, 2022
- Shareholder voteFeb 2, 2022
- Other material eventJan 7, 2022
- Entered a material agreement · Director / officer change · Other material eventDec 13, 2021
- Results of operationsNov 4, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.